There is no effective therapy for @entity2662 )-associated @entity602 /tropical @entity3500 ( @entity3498 / @entity3499 ). Glucocorticoids are effective to reduce the motor disability in these @entity1 , but its role as anti- @entity508 drugs is unknown. Here it is reported the use of @entity288 in @entity3498 / @entity3499 . The goal was to find reliable molecular markers linked to treatment effectiveness. The clinical efficacy of @entity288 was studied in 22 @entity3498 / @entity3499 . The treatment was a single dose of 7.0   mg of systemic @entity5935 . Pre-treatment samples were obtained immediately before @entity134 administration and post-treatment samples were collected after 5 days. @entity16 was evaluated by the Osame's Motor Disability Scales. Relative levels of @entity13181 , @entity403 , @entity688 , @entity2533 , @entity4386 , and @entity28267 mRNA were measured and the percentage of @entity404 (+) @entity403 (+) and @entity404 (+) @entity13181 (+) populations was quantified in PBMCs by real-time PCR and flow cytometry, respectively. The same parameters were studied in eight untreated carriers. @entity5935 treatment showed neurological improvement in 21 @entity3498 / @entity3499 @entity1 , with one @entity1 without response to treatment. This therapy was associated with a decrease in @entity13181 mRNA load and @entity404 (+) @entity13181 (+) T cells in @entity3498 / @entity3499 . Simultaneously, an increase in @entity403 mRNA and @entity404 (+) @entity403 (+) T cell was detected in these @entity1 . The other markers studied had no significant changes after treatment. Clinical improvement in @entity5935 -treated @entity3498 / @entity3499 was associated with an inverse relationship between a decrease in @entity13181 and an increase in @entity403 at the mRNA and protein levels. These results suggest that both @entity13181 and @entity403 may represent potential biomarkers for drug treatment assessments in @entity3498 / @entity3499 .

Molecular and clinical effects of @entity5935 in @entity2662 -associated XXXX /tropical @entity3500 @entity1 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3499 :: ('7057', 'Gene') :: ['TSP'] @entity28267 :: ('8784', 'Gene') :: ['GITR'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity3500 :: ('MESH:D020336', 'Disease') :: ['spastic paraparesis'] @entity508 :: ('MESH:D009128', 'Disease') :: ['spastic'] @entity602 :: ('MESH:D013118', 'Disease') :: ['myelopathy'] @entity5935 :: ('MESH:D001623', 'Chemical') :: ['Betamethasone', 'betamethasone'] @entity16 :: ('MESH:D009422', 'Disease') :: ['Neurological disability'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity2533 :: ('7040', 'Gene') :: ['TGF-b'] @entity403 :: ('50943', 'Gene') :: ['Foxp3'] @entity13181 :: ('6900', 'Gene') :: ['Tax'] @entity688 :: ('3586', 'Gene') :: ['IL-10'] @entity3498 :: ('MESH:D015493', 'Disease') :: ['HAM'] @entity4386 :: ('1493', 'Gene') :: ['CTLA-4'] @entity2662 :: ('11908', 'Species') :: ['human T-cell lymphotropic virus type I (HTLV-I'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity602 :: (MESH:D013118,Disease) :: ['myelopathy']
